Cargando…
Fasting reduces the incidence of vincristine‐associated adverse events in dogs
Fasting has been shown to decrease chemotherapy‐associated adverse events (AEs), in part through insulin‐like growth factor (IGF‐1) reduction, and may induce a protective effect on normal cells during chemotherapy treatment in mice and people. The purpose of this study was to evaluate the effect of...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7891372/ https://www.ncbi.nlm.nih.gov/pubmed/33448618 http://dx.doi.org/10.1111/vco.12638 |
_version_ | 1783652684479332352 |
---|---|
author | Duckett, Margaret E. Curran, Kaitlin M. Leeper, Haley J. Ruby, Carl E. Bracha, Shay |
author_facet | Duckett, Margaret E. Curran, Kaitlin M. Leeper, Haley J. Ruby, Carl E. Bracha, Shay |
author_sort | Duckett, Margaret E. |
collection | PubMed |
description | Fasting has been shown to decrease chemotherapy‐associated adverse events (AEs), in part through insulin‐like growth factor (IGF‐1) reduction, and may induce a protective effect on normal cells during chemotherapy treatment in mice and people. The purpose of this study was to evaluate the effect of fasting on constitutional, bone marrow and gastrointestinal (GI) AEs, and serum glucose, IGF‐1 and insulin levels in dogs receiving vincristine. The study was a prospective, crossover clinical trial in tumour‐bearing dogs. Dogs were randomized to be fasted for 24 to 28 hours prior to and 6 hours following their first or second vincristine treatment, and fed normally for the alternate dose. A significant reduction in nausea, anorexia, lethargy and serum insulin was observed when dogs were fasted; however, no significant differences were found in other GI symptoms, neutrophil count, serum glucose or IGF‐1. Fasting prior to vincristine therapy is a safe and effective treatment modality that helped mitigate constitutional and GI AEs in tumour‐bearing dogs. |
format | Online Article Text |
id | pubmed-7891372 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Blackwell Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-78913722021-03-02 Fasting reduces the incidence of vincristine‐associated adverse events in dogs Duckett, Margaret E. Curran, Kaitlin M. Leeper, Haley J. Ruby, Carl E. Bracha, Shay Vet Comp Oncol Original Articles Fasting has been shown to decrease chemotherapy‐associated adverse events (AEs), in part through insulin‐like growth factor (IGF‐1) reduction, and may induce a protective effect on normal cells during chemotherapy treatment in mice and people. The purpose of this study was to evaluate the effect of fasting on constitutional, bone marrow and gastrointestinal (GI) AEs, and serum glucose, IGF‐1 and insulin levels in dogs receiving vincristine. The study was a prospective, crossover clinical trial in tumour‐bearing dogs. Dogs were randomized to be fasted for 24 to 28 hours prior to and 6 hours following their first or second vincristine treatment, and fed normally for the alternate dose. A significant reduction in nausea, anorexia, lethargy and serum insulin was observed when dogs were fasted; however, no significant differences were found in other GI symptoms, neutrophil count, serum glucose or IGF‐1. Fasting prior to vincristine therapy is a safe and effective treatment modality that helped mitigate constitutional and GI AEs in tumour‐bearing dogs. Blackwell Publishing Ltd 2020-08-26 2021-03 /pmc/articles/PMC7891372/ /pubmed/33448618 http://dx.doi.org/10.1111/vco.12638 Text en © 2020 The Authors. Veterinary and Comparative Oncology published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Duckett, Margaret E. Curran, Kaitlin M. Leeper, Haley J. Ruby, Carl E. Bracha, Shay Fasting reduces the incidence of vincristine‐associated adverse events in dogs |
title | Fasting reduces the incidence of vincristine‐associated adverse events in dogs |
title_full | Fasting reduces the incidence of vincristine‐associated adverse events in dogs |
title_fullStr | Fasting reduces the incidence of vincristine‐associated adverse events in dogs |
title_full_unstemmed | Fasting reduces the incidence of vincristine‐associated adverse events in dogs |
title_short | Fasting reduces the incidence of vincristine‐associated adverse events in dogs |
title_sort | fasting reduces the incidence of vincristine‐associated adverse events in dogs |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7891372/ https://www.ncbi.nlm.nih.gov/pubmed/33448618 http://dx.doi.org/10.1111/vco.12638 |
work_keys_str_mv | AT duckettmargarete fastingreducestheincidenceofvincristineassociatedadverseeventsindogs AT currankaitlinm fastingreducestheincidenceofvincristineassociatedadverseeventsindogs AT leeperhaleyj fastingreducestheincidenceofvincristineassociatedadverseeventsindogs AT rubycarle fastingreducestheincidenceofvincristineassociatedadverseeventsindogs AT brachashay fastingreducestheincidenceofvincristineassociatedadverseeventsindogs |